Table 1.
IRS and Her2-score of the SSTR-staining, comparison of monoclonal (UMB-4) and polyclonal antibodies in pancreatic neuroendocrine tumors
| IRS SSTR5 poly Score / Frequency (%) | Pancreas (n=65) | Her2/neu Score / Frequency (%) | Pancreas (n=65) |
| 0 | 18 (27.7%) | 0 | 29 (44.6%) |
| 1-3 | 34 (52.3%) | 1+ | 22 (33.8%) |
| 4-8 | 13 (20.0%) | 2+ | 14 (20%) |
| 9-12 | 0 (0%) | 3+ | 0 (0%) |
| SSTR5 positive total | 13/65 (20%) | 14/65 (21.5%) | |
| IRS SSTR5 mono Score / Frequency (%) | Pancreas (n=66) | Her2/neu Score / Frequency (%) | Pancreas (n=66) |
| 0 | 23 (34.8%) | 0 | 32 (48.5%) |
| 1-3 | 23 (34.8%) | 1+ | 15 (22.7%) |
| 4-8 | 15 (22.7%) | 2+ | 13 (19.7%) |
| 9-12 | 5 (7.6%) | 3+ | 6 (9.1%) |
| SSTR5 positive total | 20/66 (30.3%) | 19/66 (28.8%) |
IRS ≥ 4 points and Her2/neu ≥ 2+ were defined positively for SSTR expression.